Coupling culturomics and metagenomics sequencing to characterize the gut microbiome of patients with cancer treated with immune checkpoint inhibitors
These findings highlight that culturomics and metagenomics can serve as complementary tools to characterize the microbiome in patients with cancer. This integrated approach uncovers specific microbiome signatures that differentiate HV from cancer patients, and identifies specific species associated with therapy response and resistance.
Authors
- A. Renaud
- Babacar Mbaye
- Bertrand Routy (ORCID: https://orcid.org/0000-0002-0756-6571)
- Wiam Belkaïd
- Arielle Elkrief (ORCID: https://orcid.org/0000-0003-1981-1535)
- Meriem Messaoudene
- Karla A. Lee (ORCID: https://orcid.org/0000-0001-5904-5586)
- A. A. Filin (ORCID: https://orcid.org/0000-0003-1670-3694)
- Myriam Benlaïfaoui
- Sebastian Hunter (ORCID: https://orcid.org/0009-0006-1783-0416)
- Somayeh Nili
- Khoudia Diop (ORCID: https://orcid.org/0000-0002-9296-563X)
- Julie Malo (ORCID: https://orcid.org/0009-0005-3613-2210)
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Centre Hospitalier de l’Université de Montréal (CA)
Publication Details
- Journal
- Gut Pathogens
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1186/s13099-025-00694-4
- Citations
- 10
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 8.06
Funders
- Canadian Institutes of Health Research